Protagonist Therapeutics, Inc
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
PTGX$136.26+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| · · · · · · · · · · · · · · · · · | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||
| · · · · Additional · · Other · · · · Total | |||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||
| · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity | |||||||||
| Three months ended September 30, 2025 | Shares | Amount | | | | | | | |
| Balance at June 30, 2025 | 62,107,572 | $1 | | $1,054,980 | $(15) | | $(386,948) | $668,018 | |
| Issuance of common stock under equity incentive and employee stock purchase plans | | 339,530 | — | | 5,659 | — | | — | 5,659 |
| Stock-based compensation expense | — | — | | 10,559 | — | | — | 10,559 | |
| Other comprehensive income | — | — | | — | 540 | | — | 540 | |
| Net loss | — | — | | — | — | | (39,339) | (39,339) | |
| Balance at September 30, 2025 | 62,447,102 | $1 | | $1,071,198 | $525 | | $(426,287) | $645,437 | |
| · · · · · · · · · · · · · · · · · | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||
| · · · · Additional · · Other · · · · Total | |||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||
| · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity | |||||||||
| Three months ended September 30, 2024 | Shares | Amount | | | | | | | |
| Balance at June 30, 2024 | | 58,762,063 | $1 | | $980,558 | $(249) | | $(438,986) | $541,324 |
| Issuance of common stock under equity incentive and employee stock purchase plans | | 759,840 | — | | 12,051 | — | | — | 12,051 |
| Stock-based compensation expense | — | — | | 10,165 | — | | — | 10,165 | |
| Other comprehensive income | — | — | | — | 1,585 | | — | 1,585 | |
| Net loss | — | — | | — | — | | (33,210) | (33,210) | |
| Balance at September 30, 2024 | 59,521,903 | $1 | | $1,002,774 | $1,336 | | $(472,196) | $531,915 | |
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · Additional · · Other · · · · Total | |||||||||||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity | |||||||||||||||||
| Nine months ended September 30, 2025 · Shares · Amount · · · · · · · | |||||||||||||||||
| Balance at December 31, 2024 | 61,035,139 | $1 | | $1,015,898 | $(82) | | $(340,522) | $675,295 | |||||||||
| Issuance of common stock under equity incentive and employee stock purchase plans | | 1,424,599 | | | — | | | 20,506 | | | — | | | — | | | 20,506 |
| Shares withheld for net settlement of tax withholding upon vesting of restricted stock units | | (12,636) | | | — | | | (479) | | | — | | | — | | | (479) |
| Stock-based compensation expense | — | — | | 35,273 | — | | — | 35,273 | |||||||||
| Other comprehensive income | — | — | | — | 607 | | — | 607 | |||||||||
| Net loss | — | — | | — | — | | (85,765) | (85,765) | |||||||||
| Balance at September 30, 2025 | 62,447,102 | $1 | | $1,071,198 | $525 | | $(426,287) | $645,437 | |||||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · Additional · · Other · · · · Total | |||||||||||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity | |||||||||||||||||
| Nine months ended September 30, 2024 · Shares · Amount · · · · · · · | |||||||||||||||||
| Balance at December 31, 2023 | | 57,708,613 | | $1 | | $952,491 | | $(105) | | $(615,710) | | $336,677 | |||||
| Issuance of common stock under equity incentive and employee stock purchase plans | 1,749,094 | — | | 22,422 | — | | — | 22,422 | |||||||||
| Shares withheld for net settlement of tax withholding upon vesting of restricted stock units | | (20,793) | | | — | | | (600) | | | — | | | — | | | (600) |
| Issuance of common stock upon exercise of Pre-Funded Warrants | | 84,989 | | | — | | | — | | | — | | | — | | | — |
| Stock-based compensation expense | — | — | | 28,461 | — | | — | 28,461 | |||||||||
| Other comprehensive income | — | — | | — | 1,441 | | — | 1,441 | |||||||||
| Net income | — | — | | — | — | | 143,514 | 143,514 | |||||||||
| Balance at September 30, 2024 | 59,521,903 | $1 | | $1,002,774 | $1,336 | | $(472,196) | $531,915 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.